To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Approves Atrisorb Tissue Regeneration Barrier With Doxycycline URL: http://www.pslgroup.com/dg/1E10AA.htm Doctor's Guide September 14, 2000
FORT COLLINS, CO -- September 14, 2000 -- Atrix Laboratories, Inc. announced that the company has received marketing clearance from the U.S. Food and Drug Administration (FDA) for its Atrisorb® FreeFlow guided tissue regeneration (GTR) barrier with the antibiotic doxycycline. The new product advances current GTR therapy by inhibiting microbial growth that can impair healing. Block Drug Corporation has the right to market the new product in the United States. As a result of FDA clearance, Atrix has earned an additional milestone payment from Block. Dr. Steve Garrett, vice president of clinical research, said, "The presence of an antibiotic inhibits bacterial growth on the barrier. This growth has been shown in a number of independent studies to limit clinical improvements. Use of Atrisorb Free Flow barrier with doxycycline resulted in statistically superior reductions in bacterial growth on the barrier for at least six weeks after surgery and barrier placement." Guided tissue regeneration barriers are used during periodontal surgery to help regenerate bone and other tissues destroyed by periodontal disease. The new barrier product incorporates the antibiotic doxycycline in the Atrisorb GTR barrier. The antibiotic is released over a period of seven days following surgery. "This has the potential to be another excellent added revenue generator for Atrix as we increase and expand the market for our dental products in the U.S. and Europe," said David R. Bethune, chairman and chief executive officer of Atrix. Related Link: Atrix Laboratories, Inc. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.